RallyBio cuts deeper, laying off 40% of workforce after halting work on lead drug
RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after discontinuing its lead drug program and just over a year after a similar cost-cutting drive.
RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after discontinuing its lead drug program and just over a year after a similar cost-cutting drive.
